Citadel Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-281,200
| Closed | -$855K | – | 15985 |
|
|
2024
Q4 | $855K | Buy |
281,200
+209,100
| +290% | +$911K | ﹤0.01% | 7383 |
|
|
2024
Q3 | $374K | Buy |
72,100
+13,200
| +22% | +$65.6K | ﹤0.01% | 8851 |
|
|
2024
Q2 | $151K | Sell |
58,900
-39,800
| -40% | -$136K | ﹤0.01% | 10335 |
|
|
2024
Q1 | $486K | Sell |
98,700
-69,000
| -41% | -$408K | ﹤0.01% | 8470 |
|
|
2023
Q4 | $1.47M | Buy |
167,700
+38,000
| +29% | +$311K | ﹤0.01% | 5922 |
|
|
2023
Q3 | $1.49M | Buy |
129,700
+8,300
| +7% | +$160K | ﹤0.01% | 5780 |
|
|
2023
Q2 | $3.07M | Sell |
121,400
-21,300
| -15% | -$664K | ﹤0.01% | 4425 |
|
|
2023
Q1 | $4.6M | Buy |
142,700
+7,200
| +5% | +$224K | ﹤0.01% | 3958 |
|
|
2022
Q4 | $2.5M | Sell |
135,500
-310,600
| -70% | -$7.1M | ﹤0.01% | 5068 |
|
|
2022
Q3 | $12M | Buy |
446,100
+368,000
| +471% | +$7.47M | ﹤0.01% | 2492 |
|
|
2022
Q2 | $1.08M | Sell |
78,100
-30,300
| -28% | -$466K | ﹤0.01% | 6842 |
|
|
2022
Q1 | $2.11M | Buy |
108,400
+28,800
| +36% | +$437K | ﹤0.01% | 5975 |
|
|
2021
Q4 | $1.3M | Buy |
79,600
+33,700
| +73% | +$562K | ﹤0.01% | 7256 |
|
|
2021
Q3 | $1.28M | Buy |
45,900
+300
| +0.7% | +$8.56K | ﹤0.01% | 7503 |
|
|
2021
Q2 | $1.35M | Sell |
45,600
-6,100
| -12% | -$176K | ﹤0.01% | 7564 |
|
|
2021
Q1 | $1.45M | Sell |
51,700
-29,700
| -36% | -$821K | ﹤0.01% | 7200 |
|
|
2020
Q4 | $2.31M | Buy |
81,400
+25,800
| +46% | +$668K | ﹤0.01% | 5067 |
|
|
2020
Q3 | $1.4M | Buy |
55,600
+23,600
| +74% | +$619K | ﹤0.01% | 5402 |
|
|
2020
Q2 | $781K | Sell |
32,000
-6,900
| -18% | -$136K | ﹤0.01% | 6283 |
|
|
2020
Q1 | $576K | Buy |
+38,900
| New | +$805K | ﹤0.01% | 6233 |
|
|
2019
Q3 | – | Sell |
-10,100
| Closed | -$131K | – | 9864 |
|
|
2019
Q2 | $131K | Sell |
10,100
-16,000
| -61% | -$202K | ﹤0.01% | 8422 |
|
|
2019
Q1 | $411K | Buy |
+26,100
| New | +$453K | ﹤0.01% | 7114 |
|
|
2018
Q1 | – | Sell |
-13,000
| Closed | -$465K | – | 8903 |
|
|
2017
Q4 | $465K | Buy |
13,000
+5,400
| +71% | +$155K | ﹤0.01% | 5765 |
|
|
2017
Q3 | $209K | Buy |
+7,600
| New | +$184K | ﹤0.01% | 6633 |
|
|
2016
Q3 | – | Sell |
-10,400
| Closed | -$141K | – | 7885 |
|
|
2016
Q2 | $141K | Buy |
+10,400
| New | +$184K | ﹤0.01% | 6046 |
|
Other funds holding RVNC
Citadel Advisors's RVNC Position: Q1 2025 in Review
Citadel Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 91,118 shares — an estimated $277K sold.
Citadel Advisors first reported a position in RVNC in Q1 2014 and held it in 33 quarters. The position peaked at $13M in Q1 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Citadel Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 91,118 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $277K.
- Citadel Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 33 quarters.
- Citadel Advisors's Revance Therapeutics, Inc. position peaked at $13M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.